This is a routine compensation filing with no trading signal. Monitor the next quarterly filing (10-Q) for any changes in cash burn rate or dilution from the RSU issuance to the CEO.
Price Chart
Executive Summary
Edesa Biotech filed an 8-K on October 23, 2026, reporting that its Board approved substantial increases in the annual base salaries of its three top executives — CEO Dr. Pardeep Nijhawan ($357,696 to $657,423), President Dr. Michael Brooks ($335,340 to $591,681), and CFO Peter Weiler ($300,000 to $525,938) — retroactive to July 1, 2026. This is a routine compensation adjustment for a small-cap biotech with no departure, resignation, or replacement event; the filing carries no material financial or strategic signal for the stock.
Key Facts
- CEO salary increased from $357,696 to $657,423 (retroactive to July 1, 2026).
- President salary increased from $335,340 to $591,681 (retroactive to July 1, 2026).
- CFO salary increased from $300,000 to $525,938 (retroactive to July 1, 2026).
- Salaries had last been adjusted in 2023.
- 90% of CEO's monthly base salary continues to be issued as fully vested restricted share units under the 2019 Equity Incentive Plan.
Financial Impact
Aggregate annual cash compensation increase of approximately $781,668 for the three named officers; no impact on revenue, earnings, or cash flow from operations.
Risk Factors
- Increased cash compensation may accelerate cash burn for a pre-revenue or early-stage biotech.
- CEO's RSU issuance creates modest dilution for existing shareholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (EDSA) — Batch item 1 | 0001171843-26-006794 |
| Document: 0001171843-26-006794-index-headers.html | 0001171843-26-006794 |
| Document: 0001171843-26-006794-index.html | 0001171843-26-006794 |
| Document: 0001171843-26-006794.txt | 0001171843-26-006794 |
| 8-K Filing (EDSA) — Batch item 5 | 0001171843-26-006794 |
| Document: 0001171843-26-006794-index-headers.html | 0001171843-26-006794 |
| Document: 0001171843-26-006794-index.html | 0001171843-26-006794 |
| Document: 0001171843-26-006794.txt | 0001171843-26-006794 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $2.59 | awaiting T+20 | — | $2.63 (+1.54%) |
Oct 15, 2026 12d ago | 8-K | $2.67 | awaiting T+20 | — | $2.63 (−1.50%) |
Oct 15, 2026 12d ago | Press Release | $2.67 | awaiting T+20 | — | $2.63 (−1.50%) |
Aug 19, 2026 9w ago | Press Release | $4.76 $4.14 | ▲ +13.03% | ▲ +13.03% | $2.63 (+44.75%) |
Jul 14, 2026 15w ago | EFFECT | $6.74 $5.52 | ▲ +18.10% | ▲ +20.59% | $2.63 (+60.98%) |
Jul 2, 2026 16w ago | S-3 | $7.50 $5.25 | ▼ −30.00% | ▼ −29.59% | $2.63 (−64.93%) |
Jun 5, 2026 20w ago | 8-K | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.63 (−51.83%) |
Jun 5, 2026 20w ago | Press Release | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.63 (−51.83%) |
May 29, 2026 21w ago | 8-K | $6.69 $8.13 | ▲ +21.52% | ▲ +22.82% | $2.63 (−60.69%) |
May 19, 2026 23w ago | Press Release | $11.95 $6.88 | ▼ −42.43% | ▼ −43.41% | $2.63 (−77.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers